美国成人中基于年龄和基于风险使用新型21价肺炎球菌结合疫苗的成本效果
本研究基于概率队列模型,比较美国成人中基于年龄和基于风险使用PCV21与PCV20的成本效果。基于年龄使用PCV21每获得一个QALY的成本为4132美元(95%CI:成本节约,18599美元),基于风险使用PCV21为成本节约。当ST4血清型占肺炎球菌病比例较高时,PCV20更具优势。
要点
- 基于年龄使用PCV21每QALY成本4132美元(95%CI:成本节约,18599美元)。
- 基于风险使用PCV21为成本节约(95%CI:成本节约,成本节约)。
- 当ST4占肺炎球菌病比例超过30%(年龄策略)或35%(风险策略)时,PCV20更优。
核心结论
- 在美国成人中,将PCV20的既往推荐替换为PCV21可改善健康结局,在65岁时产生适度成本,并降低基于风险推荐的成本。
- 在ST4占肺炎球菌病比例较高的地区,PCV20预计比PCV21预防更多疾病并降低成本。
研究设计与样本
- 研究采用概率队列模型,分别模拟所有65岁人群(基于年龄)和42岁人群(基于风险至64岁,65岁时基于年龄)。
- 使用蒙特卡洛模拟估算不同疫苗策略下的免疫成本、医疗成本、非医疗成本和总体疾病负担。
- 模型追踪住院侵袭性肺炎球菌病(IPD)和住院及门诊非菌血症性肺炎球菌肺炎(NBP)。
- 成本以2023年美元报告,所有未来成本和结局按每年3%贴现。
主要发现
- 基于年龄使用PCV21每获得一个质量调整生命年(QALY)的成本为4132美元(95%置信区间[CI]:成本节约,18599美元)。
- 基于风险使用PCV21为成本节约(95%CI:成本节约,成本节约)。
- 当ST4导致超过30%的肺炎球菌病时,基于年龄使用PCV21相比PCV20为劣势(QALYs更低且成本更高)。
- 当ST4导致超过35%的肺炎球菌病时,基于风险使用PCV21同样为劣势。
关键数值与推荐
- 2024年6月,免疫实践咨询委员会推荐PCV21作为PCV15或PCV20的替代方案,用于所有未接种PCV的65岁及以上成人(基于年龄)以及19-64岁有增加肺炎球菌病风险条件的成人(基于风险)。
- PCV21针对的血清型组合与PCV20不同。
- 由于PCV21不含血清型4(ST4),研究检验了模型对ST4流行率的敏感性。
临床怎么用
- 在美国成人中,将PCV20的既往推荐替换为PCV21可改善健康结局,在65岁时产生适度成本,并降低基于风险推荐的成本。
- 在ST4占肺炎球菌病比例较高的地区,PCV20预计比PCV21预防更多疾病并降低成本。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In June 2024, the Advisory Committee on Immunization Practices recommended 21-valent pneumococcal conjugate vaccine (PCV21) as an alternative to 15-valent or 20-valent PCV (PCV15 or PCV20) for all PCV-unvaccinated adults aged ≥65 years (age-based) and for adults aged 19-64 years with conditions that increase the risk for pneumococcal disease (risk-based). PCV21 is effective against a different set of serotypes than PCV20. OBJECTIVE: We conducted a cost-effectiveness analysis of age-based and risk-based use of PCV21 compared with PCV20 among adults in the US. METHODS: We utilized probabilistic cohort models of all 65-year-olds (age-based) and 42-year-olds (risk-based through age 64 years and age-based at age 65 years). Monte Carlo simulation was used to estimate immunization costs, medical costs, non-medical costs, and overall disease burden under different vaccine strategies. The model tracked inpatient invasive pneumococcal disease (IPD) and non-bacteremic pneumococcal pneumonia (NBP) in inpatient and outpatient settings. Since PCV21 does not contain serotype 4 (ST4), we examined the sensitivity of our model to ST4 prevalence. Costs were reported in 2023 US dollars. All future costs and outcomes were discounted at 3 % per year. RESULTS: Age-based use of PCV21 costs $4132 (95 % confidence interval [CI]: cost-saving, $18,599) per quality-adjusted life year (QALY) gained. Risk-based use of PCV21 was cost-saving (95 % CI: cost-saving, cost-saving). Age-based use of PCV21 was dominated (had lower QALYs and higher costs) compared with PCV20 when ST4 caused >30 % of pneumococcal disease. Similarly, risk-based use of PCV21 was dominated when ST4 caused >35 % of pneumococcal disease. CONCLUSION: Among US adults, replacing the previous recommendation of PCV20 with PCV21 improved health outcomes, incurred modest costs at age 65, and decreased costs for risk-based recommendations. In areas where ST4 comprises a high percentage of pneumococcal disease, however, PCV20 is expected to prevent more disease and reduce costs compared to PCV21.
引用
- Stoecker C, Wang Y, Leidner AJ, et al. Cost-effectiveness of age-based and risk-based use of the new 21-valent pneumococcal conjugate vaccine among U.S. adults. Vaccine. 2025. PMID: 41274026. doi:10.1016/j.vaccine.2025.127940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。